Immunotherapy in Relapsed-Refractory SCLC | OncLive
Immunotherapy in Relapsed-Refractory SCLC | OncLive
Dec 17, 2019
onclive.com
ES-SCLC Paradigm Change Following IMpower133 and CASPIAN Trials: What Is the Role of Durvalumab in 1L Setting? How Does the Addition of Atezolizumab to CP/ET Affect Patient Outcomes?
ES-SCLC Paradigm Change Following IMpower133 and CASPI…
636 viewsAug 17, 2020
vumedi.com
Immunotherapy: Changing Patient Outcomes in SCLC
Immunotherapy: Changing Patient Outcomes in SCLC
Jul 1, 2019
reachmd.com
Extensive-Stage Small Cell Lung Cancer Treatment | TECENTRIQ® (atezolizumab)
6:14
Extensive-Stage Small Cell Lung Cancer Treatment | TECENTRIQ® (…
Dec 18, 2023
tecentriq.com
ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC | OncLive
9:15
ADRIATIC Trial: Durvalumab, cCRT Timing, and Survival in LS-SCLC | …
Jun 25, 2024
onclive.com
Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcomes and Implications | OncLive
Durvalumab in LS-SCLC: Exploring Phase 3 ADRIATIC Trial Outcome…
1 week ago
onclive.com
Dr Shields on Incorporating Tarlatamab into Clinical Practice for ES-SCLC | OncLive
Dr Shields on Incorporating Tarlatamab into Clinical Practice f…
Jul 30, 2024
onclive.com
Guidelines for Managing Chemo-Induced Myelosuppression in ES-…
Sep 2, 2021
onclive.com
Standard of Care for ES-SCLC | OncLive
Mar 25, 2021
onclive.com
Real-World Use of Durvalumab Tremelimumab in Advanced HCC …
Oct 28, 2022
onclive.com
Using Trilaciclib for Treatment of ES-SCLC | OncLive
Apr 2, 2021
onclive.com
Management of ES-SCLC: Second Line and Beyond | OncLive
1 week ago
onclive.com
Dr. Stevenson on Ongoing Research Efforts in ES-SCLC | OncLive
Aug 23, 2021
onclive.com
Treating for Stage III NSCLC After Progression on Durvalumab | Onc…
Jul 13, 2020
onclive.com
Expanded Access to Trilaciclib for Patients With ES-SCLC | OncLive
Sep 16, 2021
onclive.com
AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab Chemot…
May 19, 2023
onclive.com
1:30
Dr Preeshagul on Emerging Treatments in SCLC | OncLive
8 months ago
onclive.com
Durvalumab in Stage III NSCLC Based on Performance Status | On…
Jul 13, 2020
onclive.com
Patient Scenario 1: Newly Diagnosed ES-SCLC With Presenc…
1 week ago
onclive.com
12:40
Real-world comparison of the efficacy and safety of atezolizuma…
Dec 17, 2024
onclive.com
24:24
Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metast…
1 week ago
onclive.com
3:31
Early-Day Infusions Boost Survival in Small Cell Lung Cancer: Study I…
2 months ago
YouTubeUniversal Lens
0:08
GO2 for Lung Cancer on Instagram: "📢 The @fda has approved Imfinzi (…
586 viewsDec 6, 2024
Instagramgo2forlungcancer
ADRIATIC: patterns of disease progression with durvalumab in L…
119 views10 months ago
YouTubeVJOncology
Durvalumab following chemoradiotherapy improves surv…
367 viewsJun 26, 2024
YouTubeecancer
3:07
The Use of Durvalumab in Locally Advanced NSCLC
283 viewsApr 16, 2018
YouTubeTargeted Oncology
Durvalumab Tolerability in Non–Small Cell Lung Cancer
1.5K viewsFeb 25, 2020
YouTubeTargeted Oncology
42:48
Immunotherapy for Lung Cancer
14.7K viewsJan 18, 2016
YouTubeGlobal Resource for Advancing Cancer Education
3:20
How Monoclonal Antibodies Treat Cancer
169.9K viewsJun 30, 2020
YouTubeNational Cancer Institute
3:46
Understanding Immunotherapy for Lung Cancer
36.6K viewsAug 6, 2020
YouTubeYou and Lung Cancer
See more videos
Static thumbnail place holder